Pramlintide
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
AstraZeneca · Phase 2 · Completed · Enrollment 258
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| 3 | Obesity or overweight | n/r | n/r | n/r | n/r |
| 4 | Obesity or overweight | n/r | n/r | n/r | n/r |